ArticleJournal of neurovirology2020
Lifetime antiretroviral exposure and neurocognitive impairment in HIV.
Article in Journal of neurovirology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Applications of Machine Learning for Cognitive Health in Older Individuals With HIV: Rapid Systematic Review.JMIR aging · 2025Pooled it
- Prevalence and risk factors of cognitive frailty in people with HIV.AIDS (London, England) · 2026Observational
- Longitudinal effects of polypharmacy on cognitive function in people with HIV.AIDS (London, England) · 2026Article
- The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- CEST MRI detects antiretroviral drug toxicities in the developing mouse brain.Frontiers in pharmacology · 2025Article
- Mental health and cognition in relation to adherence to antiretroviral therapy among people living with HIV in Kazakhstan: a cross-sectional study.Journal of the International AIDS Society · 2024Article
- Cognitive Impairment in People Living with HIV and the Impact of Mood: Results from a Cross-Sectional Study.Journal of clinical medicine · 2024Article
- Review
- Verbal Memory Performance and Depressive Symptoms in Persons with Treated HIV.AIDS and behavior · 2023Article
- Human iPSC-derived neurons reveal NMDAR-independent dysfunction following HIV-associated insults.Frontiers in molecular neuroscience · 2023Article
- Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors.Frontiers in toxicology · 2023Article
- Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model.Frontiers in pharmacology · 2023Article
- HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea.Viruses · 2022Article
- Longitudinal Effects of Combination Antiretroviral Therapy on Cognition and Neuroimaging Biomarkers in Treatment-Naive People With HIV.Neurology · 2022Article
- Degree of Polypharmacy and Cognitive Function in Older Women with HIV.AIDS research and human retroviruses · 2022Article
- Sirtuins Modulation: A Promising Strategy for HIV-Associated Neurocognitive Impairments.International journal of molecular sciences · 2022Review
- Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting.PloS one · 2022Article
- Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.Molecular neurobiology · 2021Article
- Longitudinal telomere length profile does not reflect HIV and childhood trauma impacts on cognitive function in South African women.Journal of neurovirology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Despite the availability of modern antiretroviral therapy (ART), neurocognitive impairment persists among some persons with HIV (PWH). We investigated the role of exposure to four major classes of ARTs in neurocognitive impairment in PWH. A single-site cohort of 343 PWH was recruited. Lifetime ART medication history was obtained from medical health records. We evaluated the role of ART exposure as a predictor of neurocognitive impairment using univariate analyses and machine learning, while accounting for potential effects of demographic, clinical, and comorbidity-related risk factors. Out of a total of 26 tested variables, two random forest analyses identified the most important characteristics of a neurocognitively impaired group (N = 59): Compared with a neurocognitively high-performing group (N = 132; F
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.